Cite
MLA Citation
Helmut Butzkueven et al.. “Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP).” Multiple sclerosis, vol. 27, 2021, pp. 410–419. http://access.bl.uk/ark:/81055/vdc_100116339056.0x00000f